Acoustic Neuroma (Vestibular Schwannoma)

Acoustic neuroma — more accurately called vestibular schwannoma — is a benign, slow-growing tumor arising from the Schwann cells that sheath the vestibular branch of the vestibulocochlear nerve (cranial nerve VIII). Despite the common name, it does not originate from the acoustic (cochlear) division of the nerve, and it is not a true neuroma. It accounts for approximately 8% of all intracranial tumors and is the most common tumor of the cerebellopontine angle.

Table of Contents

  1. What Is Acoustic Neuroma?
  2. Epidemiology and Types
  3. Symptoms and Clinical Presentation
  4. Diagnosis and Imaging
  5. Grading and Size Classification
  6. Management Options
  7. Microsurgery: Approaches and Outcomes
  8. Stereotactic Radiosurgery
  9. Observation and Active Monitoring
  10. Complications and Long-Term Effects
  11. NF2-Related Bilateral Disease
  12. References & Research
  13. Featured Videos

What Is Acoustic Neuroma?

Acoustic neuroma is a misnomer that persists in clinical and lay usage. The tumor is a schwannoma — a benign neoplasm composed of Schwann cells — and it arises from the vestibular division of cranial nerve VIII, not the cochlear (acoustic) division. The tumor originates most commonly within the internal auditory canal (IAC) and expands into the cerebellopontine angle (CPA) cistern as it grows.

Because the tumor is benign and slow-growing (average growth rate 1–2 mm/year), it rarely causes acute neurological emergencies. However, over years it can compress adjacent cranial nerves (V, VII) and, if large enough, the brainstem itself. The overwhelming majority are unilateral and sporadic; bilateral tumors are the hallmark of neurofibromatosis type 2 (NF2).

Key anatomical facts that guide management:

Epidemiology and Types

The incidence of vestibular schwannoma has risen over recent decades, largely due to increased detection by MRI. True incidence is approximately 1.0–1.7 per 100,000 per year.

Sporadic (Unilateral)

Sporadic acoustic neuromas account for roughly 90–95% of cases. They are almost always unilateral and are diagnosed most commonly between ages 40 and 60. The etiology involves somatic (non-inherited) loss-of-function mutations in the NF2 tumor suppressor gene on chromosome 22q12, which encodes the protein merlin (schwannomin). Loss of merlin leads to unchecked Schwann cell proliferation.

Risk factors are limited. The only well-established environmental risk factor is prior therapeutic head and neck irradiation. The INTERPHONE and CERENAT studies examined mobile phone use and found no convincing association with ipsilateral tumor risk after accounting for recall bias.

NF2-Related (Bilateral)

Neurofibromatosis type 2 is an autosomal dominant condition caused by germline mutations in NF2. Bilateral vestibular schwannomas are the defining feature, typically presenting in the second or third decade of life — decades earlier than sporadic tumors. NF2 patients also develop meningiomas, spinal ependymomas, and other cranial nerve schwannomas. Management is far more complex because preservation of hearing and facial function in both ears is the overriding priority.

Symptoms and Clinical Presentation

Symptoms develop insidiously because the tumor grows slowly and the brain compensates for gradual changes in vestibular and auditory function.

Unilateral Sensorineural Hearing Loss

The most common first symptom, present in 90–95% of cases at diagnosis. The hearing loss is typically high-frequency and progressive over months to years. Sudden sensorineural hearing loss — an audiological emergency — is the presenting symptom in approximately 10–15% of cases and must always prompt acoustic neuroma workup. Audiometric testing typically shows asymmetric sensorineural hearing loss with disproportionately poor speech discrimination relative to pure-tone thresholds (rollover phenomenon).

Tinnitus

High-pitched, unilateral tinnitus affecting the involved ear is present in up to 70% of patients. It is often described as a continuous ringing or hissing and may precede measurable hearing loss by months. Unilateral tinnitus in any adult warrants evaluation to exclude a retrocochlear lesion.

Imbalance and Vestibular Dysfunction

Because the tumor grows from vestibular nerve fibers, vestibular symptoms might be expected as the first manifestation — but most patients experience only mild, chronic disequilibrium rather than acute vertigo. The slow growth rate allows central vestibular compensation. Acute episodic vertigo is more typical of Meniere's disease and should prompt a different diagnostic workup, though the two conditions can co-exist.

Facial Numbness

Large tumors (Koos grade III–IV) may compress the trigeminal nerve (CN V) as it traverses the CPA cistern, producing ipsilateral facial numbness or paresthesia. This is an important clinical sign indicating tumor size that likely warrants intervention.

Facial Weakness

Facial nerve (CN VII) weakness is rare at presentation because CN VII has remarkable resilience to gradual compression. Its presence is a worrying prognostic sign, either suggesting very large tumor size or, rarely, a malignant mimicker. Pre-operative CN VII function is graded using the House-Brackmann scale (I = normal, VI = complete paralysis) and is the primary determinant of expected post-surgical outcome.

Brainstem and Cerebellar Compression

Very large tumors (>4 cm) can compress the brainstem and fourth ventricle, causing headache, ataxia, dysphagia, and hydrocephalus. These cases require urgent surgical decompression.

Diagnosis and Imaging

Gadolinium-Enhanced MRI (Gold Standard)

Gadolinium-enhanced MRI of the internal auditory canals with thin-slice (≤3 mm) axial and coronal T1-weighted sequences through the CPA-IAC is the definitive diagnostic test. The tumor enhances avidly and homogeneously on T1 post-contrast. MRI detects tumors as small as 2–3 mm and defines the relationship of the mass to the brainstem, cerebellum, and facial nerve.

Auditory Brainstem Response (ABR)

ABR measures the electrophysiological response of the auditory pathway to click stimuli. Acoustic neuromas typically produce prolonged interpeak latency between waves I and V (I-V interval >4.4 ms), reflecting retrocochlear conduction delay. Sensitivity is approximately 90–95% but falls for small intracanalicular tumors. ABR is used primarily for screening in patients with equivocal audiometry results when MRI is not immediately available.

Audiometry

Pure-tone audiometry, speech discrimination testing, and acoustic reflex measures together form the standard audiometric battery. The "50/50 rule" (≥50 dB asymmetry at any frequency or ≥50% asymmetry in speech discrimination) has historically been used as a referral criterion for further imaging, though MRI is now recommended for any unexplained asymmetric sensorineural hearing loss.

High-Resolution CT

CT of the temporal bone is less sensitive than MRI for soft-tissue definition but reveals bony anatomy important for surgical planning. IAC widening or erosion on CT is a classic sign of acoustic neuroma and may be the first imaging finding in resource-limited settings.

Grading and Size Classification

Two grading systems are used clinically to stratify tumor size and guide treatment decisions.

Koos Classification

Hannover Classification

The Hannover system stratifies further by intrameatal extension and brainstem displacement, providing more granular surgical planning guidance. Both systems are routinely reported in the surgical literature to enable cross-study comparison.

Management Options

Three management strategies exist: observation, microsurgery, and stereotactic radiosurgery. The optimal choice depends on tumor size, growth rate, patient age, baseline hearing, contralateral ear function, and patient preference.

No single strategy is universally superior. Decision-making is best done at a multidisciplinary skull-base tumor board involving neurotology, neurosurgery, and radiation oncology. Shared decision-making with the patient — weighing the chances of tumor control, hearing preservation, and facial nerve function — is central to good care.

Microsurgery: Approaches and Outcomes

Microsurgical resection offers the possibility of complete tumor removal and is often favored for larger tumors or in younger patients where long-term growth control is paramount.

Retrosigmoid (Suboccipital) Approach

The most versatile approach, used for tumors of all sizes. A craniotomy behind the sigmoid sinus provides access to the CPA and IAC. Advantage: hearing preservation is possible if cochlear nerve integrity is maintained. Limitation: working through a posterior-lateral corridor means the facial nerve is encountered after tumor bulk has been debulked; requires IAC drilling to reach the fundal tumor extension.

Translabyrinthine Approach

Removes the labyrinth (sacrificing hearing permanently) to create direct access to the IAC and CPA. Used when hearing is already non-serviceable or for large tumors where the neurosurgeon needs the widest possible corridor. Advantage: the facial nerve can be identified at the lateral (fundal) end of the IAC before tumor dissection begins, reducing the risk of inadvertent injury. Limitation: irreversible hearing loss.

Middle Fossa Approach

Used almost exclusively for small intracanalicular tumors with serviceable hearing. A temporal craniotomy above the ear gives superior access to the IAC roof. Technically demanding; carries higher risk of temporal lobe retraction injury and is typically reserved for experienced skull-base surgeons.

Facial Nerve Outcomes

Preservation of facial nerve anatomical continuity is achievable in >95% of cases in experienced centers. However, anatomical preservation does not guarantee immediate functional normality. Neurapraxia from traction during dissection can produce temporary paresis that resolves over 6–18 months. House-Brackmann grade I-II at one year is achieved in approximately 80–90% of patients with small tumors operated at high-volume centers.

Stereotactic Radiosurgery

Stereotactic radiosurgery (SRS) delivers a single high-dose fraction of ionizing radiation to the tumor with sub-millimeter precision, exploiting the steep dose fall-off to spare adjacent brainstem and facial nerve.

Gamma Knife Radiosurgery

The gold standard for SRS in acoustic neuroma. A marginal dose of 12–13 Gy is applied to tumors ≤3 cm (Koos I-III). Long-term tumor control rates (defined as absence of growth requiring further intervention) are 90–97% at 10 years. Hearing preservation rates at 5 years are approximately 50–70% for patients with serviceable pretreatment hearing. Facial nerve function is maintained at House-Brackmann grade I-II in >95% of patients at experienced centers.

CyberKnife (Fractionated Stereotactic Radiotherapy)

Delivers the dose in 3–5 fractions, potentially reducing cochlear and facial nerve dose while maintaining tumor control. Used for tumors where single-fraction dosimetry is suboptimal due to proximity to the cochlea or brainstem.

SRS vs. Surgery

For tumors ≤3 cm, SRS avoids operative morbidity and general anesthesia but does not remove the tumor — it arrests growth and causes fibrosis. Long-term follow-up with serial MRI is mandatory. Tumor enlargement post-SRS (15–20% transiently "swell" in the first 6–12 months, pseudoprogression) must be distinguished from true treatment failure before additional intervention.

Observation and Active Monitoring

Many acoustic neuromas — particularly small, incidentally discovered intracanalicular tumors — may be safely observed with serial MRI rather than immediate intervention. This is especially appropriate for:

Multiple natural history studies show that approximately 40–50% of sporadic acoustic neuromas demonstrate no measurable growth over a 3–5 year observation period. However, 30–40% do grow, and growth is unpredictable. A standard observation protocol involves MRI at 6 months after diagnosis, then annually for 3–5 years, then every 2–3 years if stable.

The decision point for intervening during observation is tumor growth, worsening hearing, or development of new symptoms. Patients should understand that waiting does not eliminate future treatment options, but that larger tumors at the time of intervention carry higher risks.

Complications and Long-Term Effects

Regardless of management modality, patients may face long-term sequelae:

NF2-Related Bilateral Disease

NF2 presents a unique management challenge: bilateral tumors threaten total deafness if both cochlear nerves are sacrificed. Management priorities shift toward hearing preservation above tumor eradication.

References & Research

Key Research Papers

  1. Koos WT, Day JD, Matula C, Levy DI. Neurotopographic considerations in the microsurgical treatment of small acoustic neurinomas. J Neurosurg. 1998;88(3):506–512. PMID: 9488306
  2. Sughrue ME, Yang I, Aranda D, et al. The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. J Neurosurg. 2010;112(1):163–167. PMID: 19552523
  3. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med. 1998;339(20):1426–1433. PMID: 9811918
  4. Myrseth E, Møller P, Pedersen PH, et al. Vestibular schwannomas: clinical results and quality of life after microsurgery or gamma knife radiosurgery. Neurosurgery. 2005;56(5):927–935. PMID: 15853467
  5. Pollock BE, Driscoll CL, Foote RL, et al. Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery. 2006;59(1):77–85. PMID: 16823303
  6. Hasegawa T, Fujitani S, Katsumata S, et al. Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years. Neurosurgery. 2005;57(2):257–265. PMID: 16094154
  7. Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046–1052. PMID: 22790112
  8. Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J. The natural history of vestibular schwannoma. Otol Neurotol. 2006;27(4):547–552. PMID: 16791048
  9. Neff BA, Welling DB. Current concepts in the evaluation and treatment of neurofibromatosis type II. Otolaryngol Clin North Am. 2005;38(4):671–684. PMID: 16039448
  10. Nakamura M, Roser F, Dormiani M, et al. Facial and cochlear nerve function after surgery of cerebellopontine angle meningiomas: clinical article. J Neurosurg. 2005;102(6):1036–1045. PMID: 15926710
  11. Baguley DM, Phelps PD, Moffat DA. Tinnitus after translabyrinthine removal of acoustic neuromas. Clin Otolaryngol Allied Sci. 1993;18(1):26–29. PMID: 8458529
  12. Nonaka Y, Watanabe K, Fukushima T, et al. Functional outcomes and patient satisfaction after surgical treatment of large vestibular schwannomas. Neurosurgery. 2011;69(4):819–829. PMID: 21623238

Back to Table of Contents

Research Papers

The following PubMed topic searches retrieve current peer-reviewed literature on Acoustic Neuroma / Vestibular Schwannoma.

  1. Vestibular schwannoma treatment outcomes
  2. Acoustic neuroma Gamma Knife radiosurgery
  3. Vestibular schwannoma hearing preservation surgery
  4. Acoustic neuroma natural history observation
  5. NF2 bilateral vestibular schwannoma
  6. Retrosigmoid translabyrinthine middle fossa approach
  7. Acoustic neuroma facial nerve outcomes
  8. Vestibular schwannoma MRI internal auditory canal

Back to Table of Contents

Connections

Back to Table of Contents